



VectivBio to be Acquired by Ironwood

May 23, 2023

Basel, Switzerland – May 23, 2023 – Cooley advised VectivBio, a clinical-stage biotech company focused on the discovery and development of treatments for severe, rare gastrointestinal (GI) conditions, on its [acquisition by Ironwood](#), with an estimated aggregate consideration of approximately \$1 billion. The deal was structured in a precedent-setting, all-cash tender offer for the Swiss Nasdaq-listed company. Partners Michal Berkner and Brandon Fenn led the Cooley team, along with associate Rita Sobral.

The acquisition of VectivBio and its lead investigational asset apraglutide provides a significant opportunity to accelerate the next growth horizon for Ironwood. The transaction has the potential to strengthen Ironwood's innovative portfolio and pipeline to advance treatment for GI diseases and redefine the standard of care for GI patients.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered **Attorney Advertising** and is subject to our [legal notices](#).

Key Contacts

Brandon W. Fenn New York	bfenn@cooley.com +1 212 479 6626
Rita Sobral London	rsobral@cooley.com +44 (0) 20 7556 4515

Sydney Sawyer London	ssawyer@cooley.com +44 20 7556 4493
Sarah Curry New York	sarah.curry@cooley.com +1 212 479 6652
Trevor Bossi Boston	tbossi@cooley.com +1 617 937 1384
Lois NaYeon Yoo New York	lyoo@cooley.com +1 212 479 6898
David Burns Washington, DC	dburns@cooley.com +1 202 728 7147
Nicollette R. Kirby Washington, DC	nkirby@cooley.com +1 202 776 2085
Barbara Mirza Santa Monica	bmirza@cooley.com +1 310 883 6465
Steven A. Zuckerman New York	szuckerman@cooley.com +1 212 479 6647
Stephanie Gentile New York	sgentile@cooley.com +1 212 479 6531
Eileen Marshall Washington, DC	emarshall@cooley.com +1 202 728 7083
Rick Jantz Santa Monica	rjantz@cooley.com +1 310 883 6493
Phil Mitchell New York	phil.mitchell@cooley.com +1 212 479 6581
Natasha Leskovsek Washington, DC	nleskovsek@cooley.com +1 202 728 7131

Megan Mojabi (Flynn) London	mflynn@cooley.com +44 20 7556 4384
--------------------------------	---------------------------------------

This information is a general description of the law; it is not intended to provide specific legal advice nor is it intended to create an attorney-client relationship with Cooley LLP. Before taking any action on this information you should seek professional counsel.

Copyright © 2023 Cooley LLP, 3175 Hanover Street, Palo Alto, CA 94304; Cooley (UK) LLP, 22 Bishopsgate, London, UK EC2N 4BQ. Permission is granted to make and redistribute, without charge, copies of this entire document provided that such copies are complete and unaltered and identify Cooley LLP as the author. All other rights reserved.